Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulzerasib + cetuximab beta + fluorouracil + leucovorin + irinotecan
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination regimen consists of fulzerasib (a covalent KRAS G12C inhibitor), cetuximab beta (an anti-EGFR monoclonal antibody), and the FOLFIRI chemotherapy regimen (fluorouracil, leucovorin, and irinotecan). It is being evaluated in clinical trials, such as the Phase II CRUCIAL study, for the first-line treatment of patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC). By combining a direct KRAS G12C inhibitor with an EGFR inhibitor and standard chemotherapy, the regimen aims to overcome EGFR-mediated feedback reactivation and adaptive resistance, which typically limit the efficacy of KRAS G12C inhibitor monotherapy in colorectal cancer.
- Brand names
- Dupert
- Other names
- CRUCIAL regimenfulzerasib + cetuximab beta + FOLFIRIfulzerasib + Enlituo + FOLFIRIfulzerasib + Enlituo + fluorouracil + leucovorin + irinotecanGFH925 + CMAB009 + FOLFIRIIBI351 + cetuximab beta + FOLFIRIIBI351 + Enlituo + FOLFIRI
02
Targets
DNATOP1 (DNA Topoisomerase I)EGFR (Epidermal growth factor receptor)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)TS (Thymidylate synthase)
Beyond the preview
Go deeper on fulzerasib + cetuximab beta + fluorouracil + leucovorin + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulzerasib + cetuximab beta + fluorouracil + leucovorin + irinotecan.